Phase II Study of Dietary Cholesterol for Smith-Lemli-Opitz Syndrome
Primary Purpose
Smith-Lemli-Opitz Syndrome
Status
Unknown status
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
diet
Sponsored by
About this trial
This is an interventional treatment trial for Smith-Lemli-Opitz Syndrome focused on measuring Smith-Lemli-Opitz syndrome, genetic diseases and dysmorphic syndromes, rare disease
Eligibility Criteria
PROTOCOL ENTRY CRITERIA: Smith-Lemli-Opitz syndrome
Sites / Locations
- Oregon Health and Science UniversityRecruiting
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00004347
First Posted
October 18, 1999
Last Updated
June 23, 2005
Sponsor
National Center for Research Resources (NCRR)
Collaborators
Oregon Health and Science University
1. Study Identification
Unique Protocol Identification Number
NCT00004347
Brief Title
Phase II Study of Dietary Cholesterol for Smith-Lemli-Opitz Syndrome
Official Title
The Effects of Dietary Cholesterol in the Smith-Lemli-Opitz Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
December 2003
Overall Recruitment Status
Unknown status
Study Start Date
November 1995 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Center for Research Resources (NCRR)
Collaborators
Oregon Health and Science University
4. Oversight
5. Study Description
Brief Summary
OBJECTIVES: I. Examine the intestinal absorption of dietary cholesterol in patients with Smith-Lemli-Opitz syndrome.
II. Measure the effect of dietary cholesterol on plasma sterol composition. III. Quantify basal cholesterol synthesis, turnover of cholesterol and 7-dehydrocholesterol, and the effects of dietary cholesterol on these parameters.
IV. Identify fecal bile acid excretion quantitatively and qualitatively in these patients.
V. Compare the incorporation of deuterated water into plasma cholesterol, 7-dehydrocholesterol, and other intermediates, and assess the effect of dietary cholesterol on this incorporation.
Detailed Description
PROTOCOL OUTLINE:
Patients are treated with 2 dietary regimens for 1 to 3 weeks: high cholesterol and cholesterol-free. Cholesterol is provided in the form of egg yolk. The absorption and metabolism of cholesterol are evaluated with plasma and fecal studies. Deuterated water is given to patients followed by analysis of deuterium in plasma cholesterol and other intermediates, including 7-dehydrocholesterol.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Smith-Lemli-Opitz Syndrome
Keywords
Smith-Lemli-Opitz syndrome, genetic diseases and dysmorphic syndromes, rare disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Enrollment
5 (false)
8. Arms, Groups, and Interventions
Intervention Type
Behavioral
Intervention Name(s)
diet
10. Eligibility
Sex
All
Minimum Age & Unit of Time
0 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
PROTOCOL ENTRY CRITERIA:
Smith-Lemli-Opitz syndrome
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William Connor
Organizational Affiliation
Oregon Health and Science University
Official's Role
Study Chair
Facility Information:
Facility Name
Oregon Health and Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239-3098
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sonja Connor
Phone
503-494-7775
Email
connors@ohsu.edu
First Name & Middle Initial & Last Name & Degree
Jennifer Penfield
Phone
503-494-7944
Email
penfield@ohsu.edu
12. IPD Sharing Statement
Learn more about this trial
Phase II Study of Dietary Cholesterol for Smith-Lemli-Opitz Syndrome
We'll reach out to this number within 24 hrs